Argenx
ARGX
#523
Rank
A$64.06 B
Marketcap
$1,054
Share price
-1.58%
Change (1 day)
79.78%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2024 (TTM): -A$99.1 Million

According to Argenx 's latest financial reports the company's current earnings are A$1.85 Billion. In 2023 the company made an earning of -A$0.5 Billion, an increase over its 2022 earnings that were of -A$1.18 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -A$99.1 Million-79.78%
2023 -A$0.5 Billion-58.25%
2022 -A$1.18 Billion
2019 -A$0.33 Billion124.95%
2018 -A$0.15 Billion132.04%
2017 -A$61.38 Million54.86%
2016 -A$39.64 Million33%
2015 -A$29.8 Million13.63%
2014 -A$26.23 Million46.25%
2013 -A$17.94 Million